Clinical Trials Logo

Filter by:
NCT ID: NCT02847091 Completed - Clinical trials for Type 2 Diabetes Mellitus

Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy

Start date: July 29, 2016
Phase: Phase 4
Study type: Interventional

The objective of this study is to assess the reduction in insulin dose from baseline at Week 24 while keeping the blood glucose levels controlled (maintaining HbA1c values) when ipragliflozin is administered once daily for 24 weeks in patients with type 2 diabetes mellitus receiving insulin therapy.

NCT ID: NCT02846532 Completed - Thrombosis Clinical Trials

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure

UNIVERSE
Start date: November 16, 2016
Phase: Phase 3
Study type: Interventional

The Purpose of this study is to characterize the single and multiple-dose pharmacokinetic (PK) and pharmacokinetic/pharmacodynamic (PK/ PD) profiles after oral rivaroxaban therapy administered to pediatric participants 2 to 8 years of age with single ventricle physiology who have completed the Fontan procedure within 4 months prior to enrollment (Part A) and to evaluate the safety and efficacy of rivaroxaban, administered twice daily (exposure matched to rivaroxaban 10 milligram [mg] once daily in adults) compared to acetylsalicylic acid (ASA), given once daily (approximately 5 milligram per kilogram [mg/kg]) for thromboprophylaxis in pediatric participants 2 to 8 years of age with single ventricle physiology who have completed the Fontan procedure within 4 months prior to enrollment.

NCT ID: NCT02840708 Completed - Clinical trials for Pulmonary Alveolar Proteinosis, Autoimmune

SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study

Start date: May 2016
Phase: Phase 1
Study type: Interventional

Objective: Evaluate Pharmacokinetics and determine the safety of GM-CSF single dose inhalation. Study Design: Pharmacokinetic open study

NCT ID: NCT02839902 Completed - Hyperlipidemia Clinical Trials

Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood

LOTUS
Start date: December 27, 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to explore the effects of 8-week treatment with omega-3-acid ethyl esters on the lipid and lipoprotein profile in the blood in hyperlipidemic patients receiving a HMG-CoA reductase inhibitor by use of HPLC in comparison with the control group of patients not treated with omega-3-acid ethyl esters.

NCT ID: NCT02837198 Completed - Hyperuricemia Clinical Trials

Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)

Start date: July 2016
Phase: Phase 2
Study type: Interventional

To investigate the pharmacodynamics, pharmacokinetics and safety of 7-day-repeated doses of FYU-981 administered orally to male hyperuricemic patients with uric acid-overproduction or uric acid-underexcretion type. In addition, to investigate the additive effects of the combination of FYU-981 and topiroxostat administered orally to male hyperuricemic patients with uric acid-overproduction type.

NCT ID: NCT02836873 Completed - Clinical trials for Type 2 Diabetes Mellitus

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

Start date: September 23, 2016
Phase: Phase 3
Study type: Interventional

This was a phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of oral administration of bexagliflozin at 20 mg versus placebo in subjects with T2DM, moderate renal impairment and inadequate glycemic control.

NCT ID: NCT02836600 Completed - Clinical trials for Advanced Solid Tumor

A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors

Start date: September 9, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the tolerability of the study drug LY3039478 in Japanese participants with advanced solid tumors.

NCT ID: NCT02836457 Completed - Clinical trials for Venous Thromboembolism

ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE

Start date: July 1, 2016
Phase:
Study type: Observational

The primary objectives of this study is to estimate the real-world safety profile of Eliquis in Japanese Venous Thromboembolism patients and to estimate the risk factors likely to affect the incidence of bleeding. Lastly, the secondary objective of this study is to estimate the real-world effectiveness profile of Eliquis in Japanese Venous Thromboembolism patients.

NCT ID: NCT02835742 Completed - Clinical trials for Pulmonary Alveolar Proteinosis, Autoimmune

Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan

Start date: September 1, 2016
Phase: Phase 2
Study type: Interventional

Objective: Determine the safety and efficacy of GM-CSF inhalation in patients with aPAP. Study Design: multi-center, randomized, double-blind, placebo- controlled, safety/efficacy study.

NCT ID: NCT02835508 Completed - Healthy Clinical Trials

Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants

Start date: June 2016
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the safety and Pharmacokinetic (PK) profile of JNJ-56021927 and its active metabolite JNJ-56142060 after single-dose administration of 60 milligram (mg), 120 mg, and 240 mg JNJ-56021927 as the tablet formulation in healthy male Japanese participants.